Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
2.04
Dollar change
-0.09
Percentage change
-4.23
%
Index- P/E1.09 EPS (ttm)1.86 Insider Own2.84% Shs Outstand37.21M Perf Week-8.11%
Market Cap77.07M Forward P/E23.72 EPS next Y0.09 Insider Trans0.00% Shs Float36.71M Perf Month-9.73%
Income101.33M PEG- EPS next Q-0.15 Inst Own39.19% Short Float2.98% Perf Quarter40.69%
Sales140.38M P/S0.55 EPS this Y-115.54% Inst Trans-0.19% Short Ratio4.19 Perf Half Y22.16%
Book/sh1.96 P/B1.04 EPS next Y139.81% ROA107.48% Short Interest1.10M Perf Year-25.27%
Cash/sh2.13 P/C0.96 EPS next 5Y- ROE458.59% 52W Range1.35 - 3.87 Perf YTD-8.52%
Dividend Est.- P/FCF- EPS past 5Y- ROI132.30% 52W High-47.29% Beta1.52
Dividend TTM- Quick Ratio3.72 Sales past 5Y487.70% Gross Margin88.36% 52W Low51.11% ATR (14)0.19
Dividend Ex-Date- Current Ratio3.72 EPS Y/Y TTM196.12% Oper. Margin52.60% RSI (14)44.74 Volatility8.28% 10.27%
Employees29 Debt/Eq0.21 Sales Y/Y TTM2436.77% Profit Margin72.18% Recom1.00 Target Price6.88
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q101.20% Payout0.00% Rel Volume1.01 Prev Close2.13
Sales Surprise472.08% EPS Surprise105.43% Sales Q/Q21.50% EarningsMay 08 AMC Avg Volume261.18K Price2.04
SMA20-13.47% SMA504.77% SMA2002.63% Trades Volume262,955 Change-4.23%
Date Action Analyst Rating Change Price Target Change
Jan-22-21Initiated Guggenheim Buy $25
Jan-06-21Initiated Cantor Fitzgerald Overweight $30
Jul-11-18Upgrade Needham Hold → Buy $5
Jun-27-18Initiated Maxim Group Buy $6
Oct-24-17Initiated Guggenheim Buy $6
Jul-10-17Initiated ROTH Capital Buy $8.50
May-09-17Downgrade Needham Buy → Hold
Mar-03-17Reiterated RBC Capital Mkts Outperform $15 → $11
Oct-20-16Initiated H.C. Wainwright Buy $14
Oct-07-16Upgrade WBB Securities Buy → Strong Buy $8
May-31-24 11:50AM
May-23-24 06:42AM
May-08-24 11:54PM
04:51PM
04:30PM
04:05PM Loading…
Apr-30-24 04:05PM
Apr-16-24 11:52AM
Apr-09-24 04:05PM
Mar-28-24 11:53PM
04:01PM
Jan-30-24 04:05PM
Jan-29-24 05:15PM
Jan-05-24 08:30AM
Dec-27-23 09:30AM
Nov-27-23 10:33AM
01:15PM Loading…
Nov-15-23 01:15PM
Nov-13-23 05:55PM
05:17PM
Oct-24-23 08:00AM
Oct-18-23 09:00PM
Oct-16-23 08:00AM
Oct-02-23 09:00PM
Sep-27-23 08:31PM
07:49AM
Sep-25-23 08:55AM
Sep-20-23 04:00AM
Sep-04-23 01:31PM
Aug-28-23 10:17PM
08:00AM
Aug-14-23 04:59PM
04:30PM Loading…
04:30PM
Aug-11-23 09:09AM
Jul-20-23 09:58AM
Jun-26-23 02:20PM
07:00AM
Jun-21-23 07:00AM
Jun-15-23 04:10PM
May-19-23 09:22AM
May-12-23 08:00AM
May-11-23 08:45AM
07:37AM
07:00AM
May-08-23 03:38PM
Apr-13-23 08:30AM
Apr-11-23 01:33PM
Mar-31-23 12:31PM
08:30AM
Mar-30-23 01:12PM
09:36AM
07:05AM
Mar-22-23 09:25AM
07:06AM
Mar-01-23 04:03PM
Jan-14-23 07:43AM
Dec-01-22 08:00AM
Nov-30-22 08:30AM
Nov-17-22 08:30AM
Nov-11-22 05:37AM
Nov-09-22 08:15AM
07:00AM
Nov-07-22 08:30AM
Nov-03-22 08:30AM
Nov-02-22 10:01AM
Nov-01-22 08:30AM
Oct-25-22 08:30AM
Oct-24-22 08:30AM
Oct-20-22 07:00AM
Oct-11-22 08:30AM
Oct-07-22 09:25AM
Sep-09-22 08:30AM
Sep-08-22 08:30AM
Sep-01-22 08:30AM
Aug-15-22 08:15AM
07:00AM
Aug-09-22 08:30AM
Aug-04-22 08:30AM
Aug-01-22 08:30AM
Jul-19-22 08:30AM
Jul-14-22 08:30AM
Jun-29-22 07:06AM
Jun-23-22 08:30AM
Jun-08-22 08:30AM
Jun-03-22 04:05PM
May-20-22 08:30AM
May-12-22 08:35AM
07:00AM
May-10-22 08:30AM
May-05-22 08:30AM
May-04-22 08:30AM
Apr-30-22 08:55AM
Apr-27-22 08:30AM
Apr-26-22 05:18PM
Apr-22-22 08:15AM
08:00AM
Apr-21-22 04:01PM
Apr-20-22 08:30AM
Apr-19-22 08:30AM
Apr-09-22 08:03AM
Apr-04-22 09:59AM
Mar-31-22 01:37PM
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.